 SOUTH SAN FRANCISCO, Calif., July 20, 2021 GLOBE NEWSWIRE -- Cytokinetics, Incorporated Nasdaq:CYTK today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of 27.50 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be 275 million. The offering is expected to close on July 23, 2021, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Cytokinetics. 